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ABSTRACT
Background Activating RAS mutations in the germline
cause rare developmental disorders such as Costello
syndrome. Somatic RAS mutations are found in
approximately 30% of human cancers. Keratinocytic
epidermal nevi (KEN) represent benign congenital skin
lesions arranged along Blaschko’s lines. A subgroup of
KEN is caused by hotspot oncogenic FGFR3 and PIK3CA
mutations in mosaicism, but the majority lack these
mutations.
Methods This study screened 72 KEN for activating
mutations in RAS genes and other oncogenes.
Results Activating RAS mutations were identified in
28/72 (39%) of KEN. HRAS was the most commonly
affected oncogene (86%), with the HRAS p.G13R
substitution representing a new hotspot mutation.
Conclusion These results indicate that activating RAS
somatic mutations leading to mosaicism result in benign
KEN of the skin. Given the prevalence of KEN, mosaic
HRAS mutations appear to be more common in patients
than germline ones. These findings identify KEN as a
mosaic RASopathy and lend further support to the notion
that genetic mosaicism is an important contributor to
disease.
INTRODUCTION
Ras proteins regulate cell proliferation, survival, and
differentiation. Somatic RASmutations resulting in
constitutive active proteins occur in 30% of human
tumours; progression models assume that these
mutations occur in the adult.1 Activating germline
RAS mutations have been identiﬁed in rare devel-
opmental disorders, such as HRAS mutations in
Costello syndrome (CS), characterised by prenatal
overgrowth and postnatal growth restriction,
coarse face, skin alterations, cardiomyopathy, and
cancer predisposition.2 3 CS overlaps with Noonan
and cardio-facio-cutaneous syndromes, caused by
activating mutations in other genes of the
RASeRAFeMAPK pathway.4e6
Non-organoid keratinocytic epidermal nevi (KEN)
are benign congenital lesions displaying a linear
distribution and resulting from genetic mosaicism;
approximately 40% of KEN harbour postzygotic
activatingmutations in FGFR3 and PIK3CA genes.7 8
However, the underlying gene mutation in the
majority of KEN still remains unknown. In this
study we show that approximately 40% of KEN are
caused by postzygotic activating RAS mutations
displaying a strong association between the geno-
type and the phenotype, with a predominance of the
HRAS p.G13R mutation.
MATERIALS AND METHODS
Sample acquisition
To identify novel genes causing KEN, we screened
one lesion from each of 72 patients for hotspot
mutations in various genes (table 1). From one
patient (no.27), three different biopsies of the KEN
were available for analysis. The KEN were retrieved
from the histopathological ﬁles of the contributing
departments in Regensburg, Barcelona, and Frie-
drichshafen. The male:female ratio of the patients
was 1:1.1, and themean age at the time of the biopsy
was 18.9613.1 years (table 1). The study was
approved by the local ethics committees of the
participating institutions and was performed
according to the Declaration of Helsinki.
Mutation analyses
DNA was isolated from manually microdissected
sections of formalin-ﬁxed, parafﬁn-embedded
tumours. FGFR3, PIK3CA, HRAS, NRAS, and KRAS
mutations were analysed using SNaPshot assays
(Applied Biosystems, Carlsbad, California, USA) as
described previously.7e10 Each mutation was
conﬁrmed by a second independent PCR. Exon 4 of
AKT1 harbouring the p.E17K hotspot mutation
was sequenced directly as described previously.11
Furthermore, direct sequencing (NRAS and HRAS)
and pyrosequencing (KRAS) were performed in
a subset of samples for validation of the mutations
in independent laboratories. To screen for muta-
tions in other oncogenes, the OncoCarta Panel v1.0
(Sequenom, San Diego, California, USA) covering
mutations in ABL1, AKT1, AKT2, BRAF, CDK4,
EGFR, ERBB2, FGFR1, FGFR3, FLT3, HRAS, JAK2,
KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, and
RETwas used for a subset of 10 KEN being wild-
type for the mutations mentioned above.12
RESULTS
Activating FGFR3 and PIK3CA mutations were
found in 16/72 (22%) and in 6/72 (8%) KEN,
respectively; hotspot oncogenic RAS mutations
were identiﬁed in 28/72 (39%) of KEN (ﬁgure 1A;
1Department of Dermatology,
University of Regensburg,
Regensburg, Germany
2Servei de Dermatologia,
Hospital del Mar-Parc de Salut
Mar, Universitat Auto`noma de
Barcelona, Barcelona, Spain
3Department of Pathology,
Josephine Nefkens Institute,
Erasmus MC, Rotterdam, The
Netherlands
4Grupo de Citogene´tica
Molecular and CIBERER,
Programa de Gene´tica del
Ca´ncer Humano, Centro
Nacional de Investigaciones
Oncolo´gicas, Madrid, Spain
5Institute of Pathology,
University of Regensburg,
Regensburg, Germany
6Department of Dermatology,
Hospital de la Santa Creu i Sant
Pau, Barcelona, Spain
7Department of Dermatology,
Hospital Sant Joan de De´u,
University of Barcelona, Spain
8Grupo de Carcinoge´nesis
Epitelial, Programa de Patologı´a
Molecular, Centro Nacional de
Investigaciones Oncolo´gicas,
Madrid, Spain
9Dermatopathology,
Friedrichshafen, Germany
10Departament de Cie`ncies
Experimentals i de la Salut,
Universitat Pompeu Fabra,
Barcelona, Spain
Correspondence to
Dr Christian Hafner, Department
of Dermatology, University of
Regensburg,
Franz-Josef-Strauss-Allee 11,
93053 Regensburg, Germany;
christian.hafner@ukr.de
CH and AT contributed equally
to this study.
Received 18 November 2011
Revised 7 February 2012
Accepted 8 February 2012
J Med Genet 2012;49:249e253. doi:10.1136/jmedgenet-2011-100637 249
Somatic mosaicism
group.bmj.com on September 4, 2017 - Published by http://jmg.bmj.com/Downloaded from 
table 1). HRAS was the most frequently altered gene: in 21/24
HRAS-mutant lesions, the p.G13R (c.37G>C) substitution was
found, thus representing a new hotspot mutation in KEN. In
one patient, this mutation was found in three biopsies at
different sites of the KEN. According to the COSMIC database
(http://www.sanger.ac.uk/genetics/CGP/cosmic/), the p.G13R
mutation is the most common HRAS mutation at codon 13 and
has been described in tumours of the thyroid gland, upper
aerodigestive tract, and urinary tract. The remaining three HRAS
mutations (p.G12C, p.G12V, and p.Q61L) have also been previ-
ously described as somatic mutations in human tumours.
Normal epidermis (n¼4) and dermis (n¼3) adjacent to the KEN,
as well as blood DNA (n¼2), were available from some patients
whose KEN had a HRAS p.G13R mutation. These normal tissues
displayed a wild type HRAS sequence (ﬁgure 1B), indicating the
somatic nature of the mutation and a strong association
between its presence and the clinical phenotype of KEN. Three
KEN harboured mutations in NRAS (p.G12D, p.P34L, and p.
Q61R) and one in KRAS (p.G12D). AKT1mutations were absent
from 47 KEN analysed. In ﬁve KEN, two mutations were found
simultaneously: HRAS (n¼3) or FGFR3 (n¼2) mutations co-
occurred with PIK3CA mutations, but HRAS and FGFR3
mutations were mutually exclusive, as reported previously in
cancers.13 Similar mutational patterns are associated with
seborrhoeic keratoses, benign epidermal tumours of the adult.7 11
Overall, no mutation was identiﬁed in 27/72 (38%) KEN. To
screen for further oncogenic mutations, 10 of these wildtype
KEN were analysed using the OncoCarta Panel that covers 238
mutations in 19 oncogenes.12 However, no additional mutations
were identiﬁed using this technique.
DISCUSSION
Despite much research on RAS, there is still incomplete
knowledge of the biological effects resulting from distinct RAS
gene mutations. In the last few years, the concept of ‘RASop-
athy ’ has been applied to developmental syndromes caused by
germline mutations in genes of the RAS/MAPK pathway.14 15
The RASopathies comprise CS, Noonan syndrome, LEOPARD
syndrome (lentigines, ECG conduction abnormalities, ocular
hypertelorism, pulmonic stenosis, abnormal genitalia, retarda-
tion of growth, and sensorineural deafness), cardio-facio-cuta-
neous syndrome, neuroﬁbromatosis type 1, hereditary gingival
ﬁbrosis, capillary malformationearteriovenous malformation
syndrome, autoimmune proliferative syndrome, and Legius
syndrome. The involvement of a common signalling pathway
explains the phenotypical overlap between many of these
disorders.
In this study we report that postzygotic RAS mutations
affecting the epidermis can cause KEN. RAS genes therefore join
FGFR3 and PIK3CA as oncogenes involved in benign congenital
proliferative skin lesions. In KEN, HRAS was the most
frequently mutated RAS gene. Germline HRAS mutations cause
CS affecting a wide variety of tissues, including the skin, and
involving both the epidermis and the dermis. Typical dermato-
logical ﬁndings in CS patients comprise papillomas, palmo-
plantar keratoderma, deep palmar and plantar creases with loose
and redundant skin, pachydermatoglyphia, abnormal ﬁngernails,
curly or wavy hair, generalised hyperpigmentation, hyperpig-
mented patches, and acanthosis nigricans.16 The latter is also
found in patients with FGFR3 germline mutations and shows
histopathological similarities to KEN. Intriguingly, germline
mutations of FGFR3 and HRAS are associated with acanthosis
nigricans, whereas somatic postzygotic mutations of both genes
in the skin result in KEN.
Mosaicism affecting RAS genes has been reported in a small
number of subjects. Two patients with a CS phenotype
harboured a p.G12S HRAS mosaicism,17 suggesting an early
occurrence of the mutation with extensive contribution to adult
tissues. The sharply demarcated plaques and papules following
Blaschko’s lines are characteristic of KEN but have not been
described in classical CS, indicating that HRAS mutant KEN are
not simply incomplete manifestations of CS. Based on the
clinical data available, none of the patients included in this study
had typical features of CS or related disorders.
The mechanisms for the distinct phenotypes associated with
germline versus postzygotic RAS mutations are unknown.
Depending on the developmental stage and fate potential of the
cells in which the mutations occur, different tissue compart-
ments and cell types will be affected (eg, epidermis only versus
both epidermis and dermis). Mosaicism implies the coexistence
of diverse cell populations within a given tissue, with potential
population cross-talk effects. Our ﬁndings suggest that in KEN
mutations occur in a subset of epidermal precursors. Differences
in the spectrum found in mosaic versus germline mutations
could also contribute to the distinct phenotype. For example,
p.G13R is the most common HRAS mutation in KEN whereas
p.G12S is characteristic of CS. Differences in the mutational
spectrum may, at least in part, be due to the strength of the
biological effects of the amino acid substitution and the associ-
ated potential embryonic lethality. Similarly, the spectrum of
KRAS mutations found in the germline in patients with devel-
opmental disorders differs from that of somatic changes in
patients with cancer.4 Interestingly, the HRAS p.G13R mutation
occurs in tumours as well as in KEN, but it has not been described
in the germline of CS patients, suggesting that although it is
tolerated in the mosaic state, it may be lethal in the germline.
The KRAS p.G12D mutationdthe most frequent somatic KRAS
substitution found in cancerdhas been described in the mosaic
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Figure 1 Mutational analysis of keratinocytic epidermal nevi. (A)
Mutation distribution (WT, wildtype). (B) The HRAS p.G13R mutation is
present in the epidermal nevus but absent from normal epidermis,
indicating a strong association between the mutation and the epidermal
hyperplasia.
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Table 1 Mutation analysis of keratinocytic epidermal nevi
No. Sex Age Localization FGFR3 PIK3CA KRAS HRAS NRAS AKT1 Normal control tissue
1 M 23 Head wt E542K wt G13R wt wt
2 F 9 Trunk right R248C NA wt wt wt wt
3 M 15 Head wt NA NA G12C wt wt wt (dermis)
4 M 17 NA wt wt wt wt wt wt
5 M 9 Neck right R248C wt wt wt wt wt
6 F 16 Arm right wt wt wt wt wt NA
7 M 21 Head right wt wt NA G13R wt wt HRAS wt (epidermis)
8 F 9 Head wt wt wt wt wt wt
9 M 23 Head wt E542K wt G13R wt wt
10 F 18 Lower leg wt wt wt wt wt wt
11 M 15 Neck left wt wt wt G13R wt wt HRAS wt (blood)
12 F 16 Trunk wt wt wt G13R wt wt
13 F 16 Neck wt wt wt wt wt wt
14 M 10 Neck G372C wt wt wt wt R41R (CGG
> CGA)
15 F 17 Trunk wt wt wt Q61L wt wt
16 M 23 Trunk wt wt wt G13R wt wt
17 M 25 NA wt wt wt G13R wt wt
18 F 1 Arm wt wt wt wt wt wt
19 M 13 Head wt wt wt wt wt wt
20 M 15 Head wt wt wt wt wt wt
21 M 16 Neck wt wt NA wt wt wt
22 F 22 Trunk wt wt wt wt wt wt
23 M 16 Trunk wt wt G12D wt wt wt
24 F 14 Neck wt wt wt G13R wt wt
25 M 11 Trunk wt wt wt wt wt wt
26 F 7 Head wt wt NA wt wt NA
27a M 12 Head NA wt wt G13R wt wt HRAS wt (dermis)
27b M 12 Head NA NA NA G13R NA NA
27c M 12 Head NA NA NA G13R NA NA HRAS wt (epidermis),
HRAS wt (dermis)
28 F 9 Trunk R248C wt NA NA NA wt
29 M 10 Trunk S249C wt wt wt wt wt
30 F 13 Head wt wt wt wt wt wt
31 F 6 Arm wt wt wt wt wt wt
32 F 1 Head wt wt wt wt NA NA
33 F 37 Arm right R248C NA wt wt wt NA
34 M 18 Head wt wt wt wt wt NA
35 M 7 Head wt wt wt wt wt NA
36 M 21 Trunk left R248C wt wt wt wt NA
37 M 30 Head R248C E545K wt wt wt NA
38 F 34 Trunk wt wt wt G13R wt NA HRAS wt (epidermis)
39 F 2 Neck wt wt wt G13R wt NA HRAS wt (epidermis),
wt (blood)
40 M 6 Neck R248C NA wt wt wt NA
41 M 16 Head right wt wt wt wt NA NA
42 F 28 Neck wt NA wt wt wt NA
43 F 25 Trunk wt NA wt G13R wt NA
44 F 14 Trunk wt wt wt G13R wt NA
45 F 16 Trunk wt NA wt wt wt NA
46 F 21 Arm right R248C NA wt wt wt NA
47 M 31 Head wt NA NA wt wt NA
48 F 19 Trunk wt NA wt wt wt NA
49 F 12 Arm left R248C NA wt wt wt NA
50 M 23 Trunk R248C wt wt wt wt NA
51 F 14 Neck R248C NA wt wt wt NA
52 F 14 Head wt E545G wt G13R wt wt
53 M 18 Trunk R248C E545G wt wt wt wt
54 M 2 Trunk wt H1047R wt wt wt wt
55 F 8 Head wt wt wt wt wt wt
56 M 10 Head R248C wt wt wt wt wt
57 M 70 Neck (sys) wt wt wt G12V wt wt
58 M 0 Arm (sys) wt wt wt wt wt wt
Continued
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state in a 6-month-old infant with a KEN and a rhabdomyosar-
coma18 and is reported here in one KEN. This amino acid
substitution has not been described in the germline, in agreement
with the fact that its constitutive expression in the mouse is
embryonic lethal.19 Again, these data suggest that KRAS p.G12D
is compatible with development and life only when it occurs in
the mosaic state. Genetic mouse models allowing the controlled
spatial and temporal activation of expression of RAS mutants in
mice are potent tools to assess these hypotheses experimentally.
KEN occur in approximately 0.1% of live births20 and about
one third of them harbour HRAS mutations. By contrast, CS is
very rare with only approximately 200 cases having been iden-
tiﬁed worldwide and a birth prevalence in the UK of approxi-
mately 1/500 000.15 Based on these numbers, postzygotic HRAS
mutations leading to mosaicism must be considerably more
prevalent in patients than germline mutations. The common
occurrence of mutations in oncogenes in KEN raises important
questions regarding the mechanism of tumour formation and
the risk of cancer in affected individuals. Secondary benign or
malignant tumours have only seldom been reported in associa-
tion with KEN, which are generally considered to be devoid of
malignant potential. However, the risk of cancer associated with
postzygotic mutations might depend on the extent of mosai-
cism, the tissues or cell types involved, and the speciﬁc muta-
tion. HRAS, KRAS, and NRAS are involved in human tumours
with a highly tissue-speciﬁc distribution that is not simply
related to tissue expression patterns. Somatic HRAS mutations
are common in tumours from the skin, cervix, upper aero-
digestive tract, urinary tract, and salivary gland according to the
COSMIC database.
In CS, HRAS germline mutations are associated with
a predisposition to rhabdomyosarcoma, neuroblastoma, and
urothelial carcinoma.21 An association between KEN and non-
cutaneous malignancies of various organs has been reported, but
the incidence and the individual risk for KEN patients is not
known.22 Although the occurrence of tumours in the patients
with KEN in this study is not known, it is conceivable that
patients with extensive KEN might have an increased risk of
internal malignancies both during childhood and in adults. We
have recently reported a subject with an extensive mosaicism for
the HRAS p.G12S mutation: the patient had a systematised
KEN and developed multiple urothelial carcinomas but did not
show classical signs of CS.23 This ﬁnding implies that oncogenic
RAS mutations found in adult solid tumours can occur already
during embryogenesis. In addition to the skin involvement, the
occurrence of urothelial carcinoma and rhabdomyosarcoma may
indicate some degree of phenotypic overlap between CS and
KEN syndrome.
Mosaicism of oncogenic mutations can cause morphologically
distinguishable lesions such as KEN in the skin, as we show here,
but it may also occur in other tissues that are not amenable to
simple tissue inspection, and contribute to cancer and non-
neoplastic disorders at these sites. The frequency of mosaicism
for Ras/MAPK pathway gene mutations in internal organs and
tissues is unknown but it could be of clinical relevance.
Our ﬁndings suggest that a proportion of KEN can be consid-
ered as a RASopathy due to activation of the RAS/MAPK
pathway bymutant RAS proteins. Because the term ‘RASopathy ’
is deﬁned by syndromes resulting from germline mutations,
we suggest the term ‘mosaic RASopathy ’ to describe KEN and
KEN syndrome18 23 as well as some rare cases of mosaic CS.17
Additional syndromes may be added to this list in the future
because the genetic basis of many mosaic disorders remains
unknown.
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